Recent retrospective analysis of the IL-1 pathway in a previously completed trial of anti-IL1 therapy in sepsis showed a mortality benefit of anti-IL1 antibody administration in patients with the highest levels of circulating IL-1ra (104). Here, IL1A is linked to Sepsis.